GlobeNewswire

RapidFire Tools, Inc. Launches Its First Channel Programme, Offering Resources to Help MSPs Profit from GDPR Compliance

Dela

The Audit Guru for GDPR(TM) Partner Programme Includes Training, Onboarding Assistance, Marketing Materials, NFR Products, and an Online Management Portal

ATLANTA, April 16, 2018 (GLOBE NEWSWIRE) -- RapidFire Tools Inc., the developers of the powerful Network Detective suite of IT assessment and compliance tools, has launched an Authorized Reseller Partner Programme in coordination with its new Audit Guru for GDPR tool. The programme marks the first time RapidFire Tools is selling one of its products exclusively through a channel of MSP partners. The new product is designed to help organisations become compliant, and remain compliant, with the sweeping EU General Data Protection Regulation (GDPR). The regulation applies to any organisation that collects and processes personal information on people who reside within in the European Union. MSPs will have the option of simply reselling Audit Guru for GDPR to their end-user clients, or offering it along with value-added consulting and ongoing compliance management services. The GDPR takes effect on 25 May 2018.

The Audit Guru for GDPR Partner Programme is available to MSPs worldwide. While GDPR primarily affects MSPs in the EU, service providers in North America and other regions in the world whose clients service or do business with customers in the EU are also impacted. The new programme provides MSPs with everything they need to create a profitable GDPR compliance practice, including:

  • Extensive product training
  • A not-for-resale Audit Guru license for MSPs to use on their own networks
  • A second Audit Guru license to resell to their first client
  • A web-based product management portal to provision and manage the tool through a consolidated interface, or a "single pane of glass"
  • White-labelled marketing materials to help MSPs sell the new offering
  • One-on-one assistance to help MSPs onboard their first Audit Guru implementations
  • Unlimited technical support

"GDPR will have a considerable impact on IT everywhere," confirms Michael Mittel, president of RapidFire Tools. "The EU represents a significant percentage of the global economy, and any organisation on the planet that maintains personal information about individuals inside the EU are required to comply with these stringent new rules."

Audit Guru for GDPR is the first purpose-built software appliance to automatically collect the data required for a proper initial GDPR audit, as well as the required on-going compliance checks. The tool will automatically generate the documentation and reporting required under the standard. Audit Guru produces dynamic, step-by-step instructions and worksheets needed to complete the assessment process.

"Until now, our tools have been sold to MSPs for internal use as part of their business development and service delivery," explained Mittel. "This launch marks a paradigm shift, wherein we've designed a product that MSPs can sell directly to the network owner. We're relying 100 percent on our MSP channel customers, whose relationships in the SMB community will quickly bring Audit Guru to market."

In addition to healthy potential margins on the resale of Audit Guru appliance subscriptions, MSPs can gain additional revenue through value-added GDPR services, ranging from simple management of the appliances, up to fully managed and ongoing GDPR Compliance-as-a-Service offerings-all supported by RapidFire Tools' services. "The success of these MSPs is not left to chance. Our Authorized Reseller Partner Programme vests us in every aspect of the process, to ensure that MSPs are well positioned to profit," Mittel added.

"We believe every organisation is going to need a product like Audit Guru," said Mark Winter, RapidFire Tools' vice president of sales. "Everything in the programme is designed to help our MSPs get up-to-speed as quickly as possible to sell Audit Guru for GDPR into their existing client sites. MSPs who partner with us can create a lucrative enhancement to their portfolios, in addition to using the tool to land new clients."

Visit https://www.rapidfiretools.com/auditguru/ or call 678-323-1300, ext. 2.

About  RapidFire Tools

RapidFire Tools, Inc is the leading global supplier of business-building technology tools for MSPs to help them close more business, offer more services, keep more customers, and make more money. The company's offerings include: a complete set of IT Assessment, Documentation and Reporting tools; tools for IT Compliance Process Automation; and tools for Insider Cyber Threat Detection & Alerting. The new Audit Guru for GDPR tool helps MSPs and internal IT professionals automate and streamline the GDPR compliance process, to help align end-customers with the technology policies required by the new EU General Data Protection Regulation. European distributors for the Audit Guru for GDPR include: Achab (Italy), Prianto (UK), and Upstream (Denmark, Iceland, Finland, Norway, Sweden).

Contact: Bob Vogel
RapidFire Tools, Inc.
bvogel@rapidfiretools.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: RapidFire Tools, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Conferences in March and April22.3.2019 08:00:00 CETPressmeddelande

Press Release 22 March 2019 Immunicum AB (publ) Announces Upcoming Conferences in March and April Immunicum AB (publ; IMMU.ST) announced today that members of the management team will attend and present at upcoming conferences in March and April. BIO-Europe Spring Date: March 25-27, 2019 Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria Participant: Sijme Zeilemaker China Focus @ Europe Vienna Date: March 27, 2019 Panel Time/Session: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Venue: Hilton Vienna Danube Waterfront, Vienna, Austria Participant: Carlos de Sousa Swedish American Life Science Summit 2019 Date: April 9-10, 2019 Presentation Date: Wednesday, April 10, 2019 Venue: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Participant: Carlos de Sousa For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 8 732 8400 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir

Immunicum AB (publ) meddelar kommande konferenser i mars och april22.3.2019 08:00:00 CETPressmeddelande

Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledningsgruppen kommer att delta och presentera vid kommande konferenser i mars och april. BIO-Europe Spring Datum: 25-27 mars 2019 Plats: Messe Wien Exhibition and Congress Center, Wien, Österrike Deltagare: Sijme Zeilemaker China Focus @ Europe Vienna Datum: 27 mars 2019 Paneltid/Sessionstid: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Plats: Hilton Vienna Danube Waterfront, Wien, Österrike Deltagare: Carlos de Sousa Swedish American Life Science Summit 2019 Datum: 9-10 april 2019 Presentationsdatum: Onsdagen 10 april 2019 Plats: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Deltagare: Carlos de Sousa För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 8 732 8400 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@i

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

Karolinska Development's portfolio company Forendo Pharma announces positive results from a Phase Ia study of FOR 62197.3.2019 09:00:00 CETPressmeddelande

STOCKHOLM, March 7, 2019. Karolinska Development's portfolio company Forendo Pharma today announces positive results from a Phase Ia study with the drug candidate FOR 6219 for the treatment of endometriosis. The results found FOR 6219 to be safe and well tolerated, with good pharmacokinetics at the doses tested. The randomized, double blind, placebo controlled Phase Ia study investigated the safety, tolerability, food effect and pharmacokinetics of single and multiple ascending oral doses of FOR 6219 in 36 healthy postmenopausal women. In the study, single doses of FOR 6219 from 2 mg up to 175 mg and multiple doses up to 150 mg twice daily for ten days were found to be safe and well tolerated. The pharmacokinetic results showed a dose proportionate exposure and no significant food effect. The safety and pharmacokinetic profile of FOR 6219 supports the initiation of a Phase Ib clinical trial in healthy premenopausal women with the aim to demonstrate Proof of Mechanism. The selective abi

Karolinska Development's portfolio company Forendo Pharma announces positive results from a Phase Ia study of FOR 62197.3.2019 09:00:00 CETPressmeddelande

STOCKHOLM, March 7, 2019. Karolinska Development's portfolio company Forendo Pharma today announces positive results from a Phase Ia study with the drug candidate FOR 6219 for the treatment of endometriosis. The results found FOR 6219 to be safe and well tolerated, with good pharmacokinetics at the doses tested. The randomized, double blind, placebo controlled Phase Ia study investigated the safety, tolerability, food effect and pharmacokinetics of single and multiple ascending oral doses of FOR 6219 in 36 healthy postmenopausal women. In the study, single doses of FOR 6219 from 2 mg up to 175 mg and multiple doses up to 150 mg twice daily for ten days were found to be safe and well tolerated. The pharmacokinetic results showed a dose proportionate exposure and no significant food effect. The safety and pharmacokinetic profile of FOR 6219 supports the initiation of a Phase Ib clinical trial in healthy premenopausal women with the aim to demonstrate Proof of Mechanism. The selective abi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum